Negligence in Product Development

Last week, a California court issued a ruling construed as being anti-industry.  The decision defines a company's legal duty to its consumers when a competing and allegedly safer drug is in the development pipeline. Astonishingly, the judicial opinion also insinuates itself into corporate product-development strategies. But does this case really establish the broad anti-industry precedent that some fear?